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As	has	been	shown,	 trace	element	supplementation	by	zinc,	e.g.,	 in	 the	 form	of	zinc	oxide	
(ZnO),	 can	 significantly	 influence	 the	anxiety	 level.	We	 investigated	 the	effects	of	ZnO	 in	
the	form	of	nanoparticles	(NPs)	in	comparison	with	conventional	ZnO	(cZnO)	in	an	animal	
model	of	anxiety.	Adult	male	Wistar	rats	were	divided	into	seven	groups,	control	(receiving	
0.9%	saline)	and	six	groups	receiving	5,	10,	and	20	mg/kg	ZnO	NPs	and	5,	10,	and	20	mg/kg	 
cZnO.	All	drugs	dispersed	in	0.9%	saline	were	 injected	i.p.;	30	min	later,	 the	anxiety	 level	
was	 estimated	 according	 to	 the	 results	 of	 the	 elevated	plus	maze	 test.	ZnO	NPs	 (5	mg/kg)	
and	cZnO	(10	and	20	mg/kg)	significantly	increased	the	normalized	values	of	time	spent	in	
open	arms	(open	arm	time,	OAT,	%)	in	comparison	with	the	control	group	(P	<	0.05).	This	
is	 indicative	of	 the	anxiolytic	effects	of	 these	components;	 in	addition,	20	mg/kg	ZnO	NPs	
reduced	 the	 intensity	 of	 locomotor	 activity	 (P	 <	 0.05).	The	 serum	 zinc	 concentration	was	
increased	manifold	 by	 anxiolytic	 doses	 of	 the	 components.	All	 doses	 increased	 serum	 pH	
to	8.05-8.10	and	kept	this	index	constant	for	24	h.	These	results	indicate	that	the	anxiolytic	
effect	of	ZnO	NPs	is	much	more	intense	than	that	of	conventional	ZnO,	but	the	introduction	
of	ZnO	NP	as	a	new	drug	for	the	treatment	of	anxiety	disorders	needs	further	investigations.
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INTRODUCTION
Anxiety	 disorders,	 being	 a	 common	 mental	 health	
problem	 in	 the	 general	 population,	 affect	 up	 to	 18%	
of	individuals	within	a	given	time	period	and	25%	of	
the	 individuals	 over	 their	 lifetime	 [1].	 Generalized	
increases	 in	 the	 level	 of	 anxiety	 tend	 to	 precede	
depression	 and	 eventually	 develop	 into	 depression.	
Unfortunately,	current	drug	therapies	for	psychological	
disorders	are	frequently	not	very	successful,	and	many	
patients	 either	 do	 not	 respond	 to	 these	 treatments	 or	
suffer	from	side	effects	[2].	
Zinc,	 an	 important	 prevalent	 trace	 element,	 is	
essential	 for	 both	 brain	 and	 systemic	 physiology.	 It	
has	been	found	in	a	great	number	of	protein	structures,	
including	 important	 enzymes	 regulating	 a	 wide	
variety	of	cellular	processes	(e.g.,	cell	division,	DNA	
synthesis,	etc.)	and	cell	 signaling	pathways	 [3].	Zinc	
modulates	 functions	 of	 many	 receptors	 (including	
AMPA/kainate,	NMDA,	and	GABA	receptors)	and	of	
voltage-gated	calcium	channels	[4-6].
During	the	past	50	years,	it	has	been	found	that	zinc	
deficiency	 in	 human	 populations	 is	 rather	 common,	
and	nutritional	deficiency	of	zinc	affects	many	people	
in	 developing	 and	 developed	 countries	 [7].	 A	 few	
studies	 showed	 that	zinc	deficiency	 induces	anxiety-
like	 behavior	 in	 animals.	 Also,	 studies	 on	 rodents	
(rats)	 suggest	a	causative	 role	 for	zinc	deficiency	 in	
the	 induction	 of	 depressive-like	 symptoms,	 reduced	
physical	 activity,	 anxiety,	 and	 anorexia	 [8].	 Data	
presented	 by	Whittle	 et	 al.	 [9]	 showed	 that	 dietary	
zinc	 deficiency	 in	 mice	 induces	 anxiety-related	
behavior	 in	 the	 novelty-suppressed	 feeding	 test	
and	 enhances	 the	 latencies	 of	 food	 consumption.	
Feeding	with	some	zinc	supplements,	such	as	ZnSO
4
,	
conventional	ZnO	(cZnO),	and	zinc	methionine,	was	
effective	 in	 reducing	 anxiety	 in	 rats	 [10].	 For	many	
years,	 feed	 manufactures	 prefer	 to	 use	 oxides	 of	
trace	minerals	 (including	 zinc).	Zinc	 oxide	 contains	
a	greater	concentration	of	this	cation,	as	compared	to	
sulfate,	and	cZnO	is	less	toxic	in	comparison	with	other	 
Zn	compounds	[11,	12].	
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With	 the	 development	 of	 nanotechnology,	 the	 use	
of	nanoparticles	(NPs)	to	replace	usual-scale	particles	
has	 increased	rapidly	[13].	Manufactured	NPs	can	be	
organic	(polymers)	or	inorganic,	such	as	nano	powders	
of	metal	oxides	and	metal	salts.	Metal	oxide	NPs	are	
the	 most	 frequently	 produced	 nanomaterials	 [14].	
ZnO	NPs	constitute	 the	extensively	used	engineered	
metal	 oxide	 nanomaterial;	 due	 to	 their	 unique	
optical,	catalytic,	 semiconducting,	piezoelectric,	and	
magnetic	 properties,	 they	 are	 widely	 produced	 and	
technologically	 applied	 [15].	 Recently,	 ZnO	 NPs	
have	 attracted	 the	 attention	 of	 biotechnologists,	 as	
they	can	be	surface-functionalized	with	a	wide	 range	
of	metal	 and	 semiconductor	 core	materials,	 thereby	
imparting	 useful	 properties	 with	 potentially	 wide-
ranging	 therapeutic	 applications	 [16].	 ZnO	NPs	 can	
be	 ingested	directly	 in	 food,	used	 in	 food	packaging,	
and	as	drug	delivery	agents.	This	ZnO	form	is	used	in	
the	 food	 industry	and	 in	biomedical	applications	due	
to	 its	antimicrobial	properties	and	also	as	anticancer	
drugs	[17].
Some	 toxicological	 studies	have,	however,	 	 shown	
that	 when	 NPs	 enter	 into	 the	 human	 body	 through	
several	distinct	routes,	including	inhalation,	ingestion,	
and	dermal	penetration,	they	can	exert	noticeable	toxic	
effects	at	different	 levels	of	biological	 systems	 [18].	
Therefore,	 a	 thorough	 investigation	of	 the	effects	of	
this	ZnO	form	on	human	health	is	necessary.	
The	aim	of	our	study	was	to	evaluate	the	effects	of	
ZnO	NPs	and	conventional	ZnO	in	the	plus	maze	test	
as	an	animal	model	of	anxiety.
METHODS
Animals and Treatment.	 Male	 albino	 Wistar	 rats	
weighing,	on	average,	200	±	20	g	were	obtained	from	
the	 animal	 house	 of	 the	 Joundi	 Shapoor	 Medical	
Sciences	University	and	accommodated	for	more	than	
a	week	in	a	room	at	24	±	1°C	with	a	controlled	12/12	h	
light–dark	cycle	(experiments	were	carried	out	during	
the	light	phase	of	the	cycle).	The	animals	were	housed	
in	 polypropylene	 cages	 (four	 per	 cage).	 Food	 and	
drinking	 water	 were	 freely	 available	 (except	 during	
brief	 test	periods).	 In	each	experiment,	eight	animals	
were	used;	each	animal	was	used	once	only.	The	drugs	
used	 in	 the	 study	 were	 ZnO	 NPs	 (<70	 nm,	 Lolitec,	
Germany)	and	cZnO	(Merk,	Germany).	Nano	ZnO	and	
cZnO	 suspensions	 were	 	 prepared	 by	 sonication	 for	
16	 min	 in	 an	 ultrasonic	 bath;	 before	 each	 injection,	
the	 suspensions	 were	 shaken	 for	 1	 min.	 Drugs	 were	
injected	i.p.	at	doses	of	5,	10,	and	20	mg/kg,	while	the	
control	group	received	0.9%	saline	(1.0	ml/kg)	[19].	
The	 size	 and	 aggregation	 of	 	 ZnO	 NPs	 were	
estimated	 in	dry	powder	and	suspension	by	scanning	
electron	microscopy	 (Hitachi	S4160,	 Japan),	and	pH	
values	 were	 measured	 by	 a	 pH	 meter	 calibrated	 in	
buffers.
Elevated Plus Maze (EPM).	 Behavioral	 testing	
was	carried	out	in	a	dimly	lighted	room.	Animals	were	
adapted	 to	 the	 testing	 room	 for	 1	 h	 prior	 to	 testing.	
A	 wooden	 plus	 maze	 consisted	 of	 two	 open	 arms	
(50×10	 cm)	 and	 two	 closed	 arms	 of	 the	 same	 size	
(with	40-cm-high	end	and	side	walls).	The	arms	were	
connected	by	a	central	10×10	cm	area;	 there	were	no	
walls	on	the	open	arms.	The	height	of	the	EPM	above	
the	 floor	was	50	 cm.	Rats	were	placed	 in	 the	 center	
of	 the	EPM	with	 their	head	 facing	an	open	arm,	 left	
undisturbed	for	5	min,	and	then	removed	and	returned	
to	 their	home	cages.	The	experimental	 sessions	were	
recorded	by	a	camera	and	analyzed	off-line	(by	maze	
router	 software,	 Iran).	A	rat	was	considered	 to	be	on	
the	 central	 platform	 when	 at	 least	 two	 paws	 were	
on	 the	 latter	 and	 in	 the	 arm	whenever	 all	 four	 paws	
were	 on	 it.	 The	 normalized	 values	 of	 time	 spent	 in	
open	arms	 (time	 in	open	arms/time	 in	open	+	closed	
arms)	⋅	100%	and	the		percentage		of	open	arm	entries,	
OAE	(number	of	open	arm	entries/number	of	open	+	
+	closed	arm	entries)	 ⋅	100%	were	used	as	measures	
of	the	anxiety	level	[20].The	distance	traveled	in	close	
and	open	arms	during	5	min	was	considered	a	measure	
of	 locomotor	 activity,	 LA;	 maze	 router	 software	
was	 used.	 In	 all	 experiments,	 the	 interval	 between	
injections	and	tests	was	30	min.
Zinc Content Analysis and pH Measurement 
in Blood Serum.	 By	 analyzing	 the	 Zn	 content	 and	
measuring	 	 pH	 in	 the	 serum	 30	min	 and	 24	 h	 after	
injection,	 we	 tried	 to	 estimate	 effective	 and	 non-
effective	 doses	 of	ZnO	NPs	 and	 compare	 them	with	
the	 effective	 doses	 of	 cZnO.	 The	 animals	 were	
anesthetized	 by	 ether,	 and	 blood	 was	 collected	 by	
cardiac	 puncture.	 Then	 the	 serum	 was	 obtained	
by	 centrifugation	 of	 whole	 blood	 at	 3,000	 rpm	 for	 
20	min;	 pH	was	measured	 by	 a	 pH	meter	 calibrated	
in	 a	 buffer,	 and	 the	 serum	Zn	 content	was	 analyzed	
by	an	atomic	absorption	spectrophotometer	 (Avanta,	
GBC,	 Austral ia) . 	 The	 spectrophotometer	 was	
calibrated	every	time	by	running	at	least	five	standard	
concentrations	 (0.25,	 0.5,	 0.75,	 1.0,	 and	 1.5	 ppm)	 
of	zinc.	
Statistical Analysis.	Numerical	data	were	expressed	
as	 means	 ±	 s.e.m.	 The	 Student’s	 t-test	 was	 used	
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for	 comparison	 of	 the	 means	 of	 unpaired	 data.	 For	
multiple	 comparisons	 between	 groups,	ANOVA	was	
used,	and	 the	LSD	post-hoc	 test	was	performed	with	
InStat	3	 software.	Differences	between	experimental	
groups	 at	 each	point	with	P	 <	0.05	were	 considered	
statistically	significant.
RESULTS
Determination	of	the	dimensions	of	ZnO	NPs	and	pH	
in	suspension	with	different	concentrations	according	
to	SEM	images	(Fig.	1)	 	 from	cZnO	dry	powder	(A),	
ZnO	 NPs	 (B),	 and	 ZnO	 NPs	 at	 different	 suspension	
concentrations	 (5,	10,	 and	20	mg/5	cm3)	 showed	 that	
the	 NPs	 tended	 to	 aggregate	 when	 the	 concentration	
was	 increased;	 the	mean	particle	 size	 increased	 from	
<70	 nm	 (in	 dry	 powder)	 to	 >133	 nm	 (at	 a	maximum	
concentration,	 20	 mg/5	 cm3).	 In	 addition,	 the	 pH	 of	
ZnO	NPs	and	cZnO	showed	acidic	properties,	and	this	
acidity	decreased	in	a	dose-dependent	manner.
Effect of cZnO on Anxiety-like Behavior.	 In	 
Fig.	2,	 the	effects	of	 i.p.	 injections	of	different	doses	
of	 cZnO	 (5,	 10,	 and	 20	 mg/kg)	 are	 shown.	 	 One-
way	ANOVA	 showed	 significant	 increases	 in	 OAT	 
(P	 <	 0.05)	 at	 doses	 of	 10	 and	 20	 mg/kg	 of	 cZnO	
(increments	66	and	52%,	as	compared	with	the	control).	
All	 doses	 of	 cZnO	 did	 not	 change	 considerably	 the	
LA	 and	OAE	 indices	 (the	OAE	 increased	 somewhat	
at	10	and	20	mg/kg	but	 insignificantly).	Thus,	cZnO	
at	a	dose	of	10	mg/kg	exerted	a	maximum	anxiolytic	
effect,	 and	we	 selected	 this	 dose	 for	 the	 subsequent	
experiments.
Effect of ZnO NPs on Anxiety-Like Behavior.	
Figure	2	also	 shows	 the	effects	of	 	 i.p.	 injections	of	
different	 doses	 of	 ZnO	NPs	 (5,	 10,	 and	 20	mg/kg).	
The		first	of	these	doses	provided	a	significant	(72%)	
increase	 in	 the	OAT	 (P	 <	 0.05),	while	ZnO	NPs	 	 in	
other	doses	did	not	 increase	 this	 index.	All	doses	of	
NPs	did	not	 influence	significantly	 the	OAE	(a	 trend	
toward	an	increase	was	noticed	at	higher	doses).	ZnO	
NPs	at	a	dose	of	20	mg/kg	 reduced	significantly	LA	
compared	 with	 the	 control	 (P	 <	 0.01).	 Thus,	 	 ZnO	
NPs	 at	 a	 dose	of	5	mg/kg	 showed	a	 clear	 anxiolytic	
A B C
D E F i g. 1.	 SEM	 images	 of	 dry	 powders	 of	
conventional	 ZnO,	 	 cZnO	 (A)	 and	 ZnO	
in	 the	 form	 of	 nanoparticles,	 ZnO	NPs	 (B,	
mean	 particle	 size	 <70	 nm)	 and	 those	 of	
suspensions	 with	 different	 concentrations	
of	ZnO	NPs,	5	mg/5	cm3		(C),	10	mg/5	cm3 
(D),	 and	 20	 mg/5	 cm3	 (E);	 mean	 particle	 
size	>133	nm.
Р и с. 1.	РЕМ-зображення	сухого	порошка	
стандартного	 ZnO,	 cZnO	 (A)	 та	 ZnO	 у	
формі	 наночасток	 –	 ZnO-NP	 (B,	 середня	
величина	розміру	частки	<70	нм),	а	також	
суспензій	з	різними	концентраціями	ZnO-
NP:	 5	 мг/5	 см3	 	 (C),	 10	 мг/5	 см3	 (D)	 та	 
20	мг/5	см3	(E);	середня	величина	розміру	
частки	>133	нм.
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effect,	and	 this	dose	was	selected	 for	 the	subsequent	
experiments.
Zinc Concentration and pH in the Blood Serum.	
There	 were	 significant	 differences	 between	 the	
serum	 zinc	 concentration	 and	 pH	 at	 all	 treatments	
in	 comparison	 with	 the	 control	 group;	 significant	
differences	between	 the	zinc	concentration	 in	 treated	
groups	 depending	 on	 the	 doses	 or	 time	 were	 also	
observed.	During	 the	 anxiety	 test,	 the	mean	 	 serum	
zinc	concentration	at	 injections	of	5	mg/kg	ZnO	NPs	
was	5.31	±	0.53	mg/liter;	 after	24	h,	 it	was	 reduced	 
to	4.29	±	0.31	mg/liter	(19.21%	reduction);	at	a	dose	
of	NPs	of	10	mg/kg,	this	index	was	22.3	±	2.6	mg/liter.	
The	respective	figures		for	10	mg/kg	cZnO	were	10.38	±	 
±	 0.9	mg/liter	 and,	 after	 24	 h,	 7.45	 ±	 0.21	mg/liter	
(28.2%	 reduction).	 Statistical	 	 analysis	 showed	 that	
the	 	 regression	coefficient	R	between	 the	zinc	serum	
concentration	and	anxiolytic	 effect	was	 	44%,	while	
between	the	values	of	pH		and	anxiolytic	effect	it	was	
0.4%.
DISCUSSION
The	elevated	plus	maze	(EPM)	test	is	one	of	the	most	
popular	tests	for	all	currently	available	animal	models	
in	 neurobiological	 anxiety	 research;	 it	 is	 used	 as	 a	
screening	 test	 for	 putative	 anxiolytic	 or	 anxiogenic	
compounds	 [21].	 Our	 results	 showed	 that	 acute	
injection	 of	 ZnO	 NPs	 in	 the	 lowest	 dose	 (5	 mg/kg)	
and	cZnO	in	greater	doses	(10	and	20	mg/kg)	induced	
anxiolytic	 effects	 in	 the	EPM	 test	 in	 adult	male	 rats.	
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F i g. 2.	 Effects	 of	 ZnO	NPs	 (5,	 10,	 and	 20	mg/kg)	 	 and	 cZnO	
(5,	10,	 and	20	mg/kg)	on	 the	mean	values	of	open	arm	 time	 (A),	
open	 arm	 entries	 (B),	 and	 locomotor	 activity	 (C)	 in	 the	 elevated	
plus	 maze	 test.	 *P	 <	 0.05	 in	 comparison	 with	 the	 saline	 group;	 
+P <	0.05	in	comparison	with	the	cZnO	(5	mg/kg)	group;	#P	<	0.05	
and	##P	<	0.01	compared	to	the	ZnO	NP	(5	mg/kg)	group;	××		P	<	0.01 
compared	to	the	cZnO	(20	mg/kg)	group.	In	all	cases,	n	=	8.
Р и с. 2.	Вплив	наночасток	ZnO	(5,	10	і	20	мг/кг)	та	стандартного	
ZnO	 (5,	 10	 і	 20	мг/кг)	 на	 середні	 величини	 часу	 перебування	
у	 відкритому	 рукаві	 (A),	 кількості	 входжень	 у	 відкритий	
рукав	 (B)	 та	 локомоторну	 активність	 (C)	 у	 тесті	 піднятого	
хрестоподібного	лабіринту.		
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Some	 studies	 agree	with	 our	 results.	 For	 example,	 it	
was	shown	that	dietary	zinc	deficiency	in	mice	induced	
anxiety-related	 behavior	 in	 the	 novelty-suppressed	
feeding	 test	 measured	 as	 enhanced	 latencies	 to	 eat	
[8,	 9].	 It	 was	 also	 shown	 that	 2-month-long	 feeding	
with	 high	 levels	 of	 zinc	 supplements,	 such	 as	 zinc	
methionine,	ZnSO
4
,	and	ZnO,	reduced	anxiety	in	rats	
subjected	to	the	EPM	test	[10].	
Figure	 2	 shows	 that	 equal	 doses	 of	ZnO	NPs	 and	
cZnO	 exert	 dissimilar	 effects	 on	 anxiety	 behavior,	
and	 the	efficacies	of	equal	doses	do	not	overlap.	The	
anxiolytic	 dose	 of	 ZnO	NPs	 corresponds	 to	 half	 of	
the	anxiolytic	dose	of	cZnO;	5	mg/kg	cZnO	exerts	no	
effect	on	anxiety.	These	differences	may	be	due	to	the	
small	size	of	ZnO	NPs	and	different	physicochemical	
properties	in	comparison	with	those	of	the	conventional	
form.	 As	 a	 result,	 ZnO	 NPs	 possessing	 greater	
mobility	and	uptake	across	biological	membranes	can	
interact	more	strongly	with	biological	tissues	[22,	23].	
The	 greater	 surface	 area	 of	 nanoparticles	 provides	
more	 reactive	groups	and	higher	 reactivities	 than	 the	
conventional	ZnO	form	[24].	
Our	data	also	showed	that	all	doses	of	cZnO	and	5	
and	10	mg/kg	ZnO	NPs	did	not	change	significantly	
LA,	while	 20	mg/kg	ZnO	NPs	 reduced	 this	 activity	
with	 practically	 no	 change	 in	 anxiety-like	 behavior.	
Thus,	 the	 anxiolytic	 effects	 of	 cZnO	 and	 ZnO	NPs	
are	 not	 related	 to	 of	 LA	 modulation.	 Higher	 doses	
of	 ZnO	 NPs	 increased	 significantly	 the	 serum	 zinc	
concentration	but	provided	no	changes	 in	 the	anxiety	
indices.	 This	 finding	 indicates	 that	 the	 lowest	 dose	
of	ZnO	NPs	used	 released	enough	zinc	 to	act	on	 the	
respective	receptor	structures;	moreover,	higher	doses	
are	 likely	 to	saturate	 the	serum	zinc	 level	but	 reduce	
the	anxiolytic	effect,	which	agrees	with	our	previous	
results	[25].	
We	found	that	in	all	treated	groups	the	pH	increased	
in	 comparison	 to	 that	 in	 the	 control	 group,	 but	 there	
were	 no	 significant	 differences	 between	 pH	 in	 all	
treated	 groups.	 Furthermore,	 statistical	 analysis	
did	 not	 show	 any	 correlation	 between	 the	 anxiety	
parameters	and	pH.	This	 fact	 indicates	 that	 increased	
pH	did	not	affect	 the	anxiety	 level	 in	our	study.	After	
24	 h,	 the	 reduction	 of	 the	 zinc	 concentration	 in	 the	
ZnO	NP	 groups	was	 lower	 than	 that	 of	 	 cZnO;	 thus,	
it	 seems	 that	 the	 clearance	 of	 ZnO	NPs	 is	 less	 than	
that	of	cZnO	[25].	Thus,	the	efficacy	of	ZnO	NPs	with	
respect	 to	 the	reduction	of	anxiety	may	depend	on	the	
ZnO	 structure	 and	 longer	 bioavailability	 more	 than	
on	 its	 concentration	 [26].	 In	 addition,	 SEM	 images	
showed	that,	with	rising	aggregation	at	higher	ZnO	NP	
concentrations,	 the	anxiolytic	effects	decreased.	Thus,	
ZnO	NP	pharmacokinetics	need	more	investigation	[25].	
Our	 unpublished	 data	 also	 showed	 that,	 10	 days	
after	acute	administration	 	of	 these	drugs,	 there	were	
no	mortality,	 loss	of	weight,	or	 	considerable	visible	
impairments	 	 in	 the	 health	 status	 of	 the	 animals,	
suggesting	 that	 injections	of	 these	doses	of	 the	drugs	
are		at	least	not	lethal.
The	 anxiolytic	 effect	 of	 ZnO	 NPs	 or	 cZnO	 may	
be	 due	 to	 the	 role	 of	 zinc	 in	 the	 anxiety-related	
neurochemical	 systems.	 In	 presynaptic	 spaces,	
zinc	 is	 co-released	 with	 glutamate,	 and	 zinc	 is	 an	
inhibitory	neuromodulator	in	the	glutamate	signalling	
system	 [27,	 28].	A	 number	 of	 studies	 indicated	 that	
glutamate	 is	 an	 important	 factor	 in	 the	 formation	of	
anxiety	and	anxious	behavior.	Blocking	of	glutamate	
NMDA	 receptors	 can	 elicit	 a	 significant	 anxiolytic	
effect	 [29].	 Several	 studies	 demonstrated	 that	
stimulation	of	NMDA	receptors	 induces	anxiogenic-
like	 behaviors	 in	 a	 variety	 of	 animal	 models	 of	
anxiety	 [30].	 Administration	 of	 competitive	 and	
noncompetitive	NMDA	receptor	antagonists	 induced	
anxiolytic	behaviors	in	humans	and	laboratory	animals	
[30].	 Electrophysiological	 studies	 showed	 that	 zinc	
weakens	 the	NMDA	 receptor-mediated	 response	 via	
two	different	mechanisms,	voltage-independent	non-
competitive	 (allosteric)	 inhibition	 responsible	 for	
reducing	the	channel	opening	frequency,	and	voltage-
dependent	 inhibition	 representing	 the	 open-channel	
blocking	 effect	 of	 zinc	 [31].	 Therefore,	 the	 release	
of	zinc	together	with	glutamate	reduces	the	ability	of	
glutamate	to	activate	postsynaptic	NMDA	receptors.
Interestingly,	 Li	 et	 al.	 [32]	 showed	 that,	 in	
the	 experiments	 combining	 zinc	 imaging	 with	
electrophysiological	 recording	 during	 electrical	
stimulation	of	rat	hippocampus	CA3	slices,	the	release	
of	zinc	from	mossy	fiber	terminals	occurs	in	a	certain	
synaptic	region	of	the	dendrites	(stratum lucidum)	that	
is	 rich	with	NMDA	receptors.	Therefore,	we	suggest	
that	 exposure	 to	 ZnO	 particles	 inhibits	 glutamate	
influences	 on	 NMDA	 receptors	 (an	 important	
neurochemical	system	is	anxious	animals).	 	
Another	alternative	way	 to	decrease	 the	glutamate	
output	 in	 the	CNS	can	be	achieved	by	 intensification	
of	 GABA	 neurotransmission.	 A	 balance	 between	
GABA	 receptor-mediated	 inhibition	 and	 glutamate	
receptor-mediated	excitation	can	 regulate	behavioral	
and	physiological	 responses	 associated	with	 anxiety	
[33,	 34].	 Zinc	 promotes	 the	 release	 of	 GABA	 from	
interneurons	 in	 the	hippocampus,	 thus	enhancing	 the	
inhibitory	effects	of	this	neurotransmitter	and	leading	
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to	decrease	in	presynaptic	release	of	glutamate	[35].	As	
a	result,	 the	release	of	zinc	from	cZnO	and	ZnO	NPs	
in	our	 study	 is	 likely	 to	be	 responsible	 for	 reducing	
the	 anxiety	 level	 via	 a	 reduction	 in	 the	 release	 of	
glutamate	and	blocking	of	NMDA	receptor	and/or	via	
increase	 in	 the	 release	 of	GABA	 and	 disrupting	 the	
balance	between	glutamate	and	an	GABA	in	the	CNS.
Thus,	 our	 study	 showed	 that	 the	 efficacy	 of	 ZnO	
NPs	 to	 reduce	 anxiety	 is	 much	 greater	 than	 that	
of	 conventional	 ZnO	 introduced	 in	 an	 equal	 dose.	
Increasing	 doses	 of	 ZnO	NPs	 do	 not	 increase	 their	
efficacy	from	the	above	aspect.	The	beneficial	effects	
of	 this	ZnO	form	may	be	 related	 to	 the	 specific	 size	
and	 structure	 or	 selectivity	with	 respect	 to	 specific	
target.
All	experimental	procedures	were	carried	out	in	accordance	
with	 international	and	 institutional	guidelines	 for	animal	care	
and	use.	
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Р	е	з	ю	м	е	
Як	 було	 показано,	 додавання	 мікроелементу	 цинку	
(наприклад,	 у	 формі	 окису	 цинку,	 ZnO)	 може	 істотно	
впливати	на	 рівень	 тривожності.	Ми	досліджували	 вплив	
ZnO	у	формі	наночасток	(НЧ)	порівняно	зі	стандартним	ZnO	
(сZnO)	на	пов’язану	з	тривогою	поведінку	у	щурів.	Дорослі	
щури	лінії	Вістар	були	поділені	на	сім	груп	–	 	контрольну	
групу	 (тварини	 отримували	 фізіологічний	 розчин)	 та	
шість	груп	щурів,	котрі	отримували	5,	10	та	20	мг/кг	ZnO-
НЧ,	 а	 також	 5,	 10	 та	 20	 мг/кг	 сZnO.	 Усі	 дисперговані	 у	
0.9	 %-му	 фізіологічному	 розчині	 препарати	 ін’єкували	
внутрішньоочеревинно;	 через	 30	 хв	 після	 ін’єкції	 рівень	
тривоги	оцінювали	 згідно	 з	результатами	тесту	піднятого	
хрестоподібного	 лабіринту.	 ZnO-НЧ	 (5	 мг/кг)	 і	 cZnO	 
(10	 та	20	мг/кг)	 істотно	 збільшували	нормовані	 величини	
часу	перебування	у	відкритих	рукавах	(%)	порівняно	з	таким	
показником	 у	 контрольній	 групі	 (P	 <	 0.05).	 Це	 свідчить	
про	анксіолітичні	ефекти	обох	агентів;	крім	того,	ZnO-НЧ	 
(20 	 мг/кг) 	 послаблював	 локомоторну	 активність	
(P 	 <	 0.05).	 Концентрація	 цинку	 в	 сироватці	 при	 дії	
агентів	 у	 анксіолітичних	 дозах	 була	 багаторазово	
збільшеною.	 Усі	 дози	 збільшували	 pH	 сироватки	 до	 
8.05–8.10	 та	 підтримували	 цей	 показник	 на	 постійному	
рівні	протягом	24	год.	Наші	результати	вказують	на	те,	що	
інтенсивність	 анксіолітичного	 ефекту	ZnO-НЧ	 є	 набагато	
більшою,	 ніж	 інтенсивність	 дії	 стандартної	 форми	 ZnO.	
Застосування	 ZnO-НЧ	 у	 якості	 нового	 терапевтичного	
препарату		у	разі	тривожних	неврозів	потребує	подаль	шого	
дослідження.	
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